Deborah Wallach
Family · Beverly Hills, CANPI 1326594144
Payments from drug & device makers
Across 80 payments — averaging $38.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AbbVie$296
- Genentech USA, Inc.$272
- Johnson & Johnson$206
- GSK$107
- Stemline Therapeutics Inc.$81
- plus $523 from 16 others
What the payments were for
- Food & beverage$1,44747%
- Education$1003%
- Other$1,54850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $1,610 |
| AbbVie | 11 | $296 |
| Genentech USA, Inc. | 11 | $272 |
| Johnson & Johnson | 6 | $206 |
| GSK | 5 | $107 |
| Stemline Therapeutics Inc. | 4 | $81 |
| Merck | 3 | $79 |
| Pfizer | 3 | $75 |
| Karyopharm Therapeutics Inc. | 1 | $63 |
| Array Biopharma Inc | 2 | $41 |
| Springworks Therapeutics, Inc. | 1 | $40 |
| Sanofi | 1 | $35 |
| Blueprint Medicines Corporation | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| AstraZeneca | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Mylan Institutional Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Beigene USA, Inc. | 1 | $12 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$3,095 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 25 | $436,964 |
| BrukinsaZanubrutinib | 18 | $270,469 |
| VerzenioAbemaciclib | 12 | $179,379 |
| Abiraterone Acetate | 29 | $167,444 |
| ImbruvicaIbrutinib | 11 | $160,395 |
| EliquisApixaban | 88 | $52,233 |
| XareltoRivaroxaban | 20 | $14,643 |
| Imatinib Mesylate | 20 | $3,428 |
| Dexamethasone | 67 | $1,481 |
| Hydroxyurea | 44 | $1,305 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $1,273 |
| ValacyclovirValacyclovir Hcl | 36 | $1,122 |
| Acyclovir | 61 | $948 |
| Prochlorperazine Maleate | 92 | $861 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 29 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $23 | $436,96425 claims |
| Beigene USA, Inc.Brukinsa | $12 | $270,46918 claims |
| PfizerEliquis | $75 | $52,23388 claims |
| Johnson & JohnsonXarelto | $206 | $14,64320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Beverly Hills
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.